New insight into the treatment of advanced differentiated thyroid cancer.

about

Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer.

P2860

Q34253418-323A9D5C-FDCA-482E-810F-36957E66C67E Q38630967-D0D5384E-BCA5-4473-8057-E2507FBB041E

P2860

New insight into the treatment of advanced differentiated thyroid cancer.

Item

http://www.wikidata.org/entity/Q36528466

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

New insight into the treatment of advanced differentiated thyroid cancer.

@ast

New insight into the treatment of advanced differentiated thyroid cancer.

@en

type

Item

label

New insight into the treatment of advanced differentiated thyroid cancer.

@ast

New insight into the treatment of advanced differentiated thyroid cancer.

@en

prefLabel

New insight into the treatment of advanced differentiated thyroid cancer.

@ast

New insight into the treatment of advanced differentiated thyroid cancer.

@en

P1476

New insight into the treatment of advanced differentiated thyroid cancer.

@en

P2093

Aparna Vijayasekaran

http://www.w3.org/2001/XMLSchema#string

Arash Safavi

http://www.w3.org/2001/XMLSchema#string

Marlon A Guerrero

http://www.w3.org/2001/XMLSchema#string

P2860

PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1

RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma.

Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma

RET oncogene activation in papillary thyroid carcinoma.

P304

437569

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/437569

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234159289

http://www.w3.org/2001/XMLSchema#string

P698

23326755

http://www.w3.org/2001/XMLSchema#string

P932

3543802

http://www.w3.org/2001/XMLSchema#string

New insight into the treatment of advanced differentiated thyroid cancer.

about

P2860

P2860

New insight into the treatment of advanced differentiated thyroid cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932